Alaunos Therapeutics, Inc. (TCRT) Tops Q3 EPS by 1c

Alaunos Therapeutics, Inc. (NASDAQ: TCRT) reported Q3 EPS of ($0.04), $0.01 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $2.9 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on Alaunos Therapeutics, Inc. (TCRT) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Ocean Power Technologies revises fiscal 2026 results after audit
• Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates